Abstract

Rheumatoid arthritis (RA) is progressive, chronic, autoimmune, systemic connective tissue disease. It affects 0,5-1% population. RA manifests as inflammation of symmetrical mainly small and medium joints with synovial hypertrophy, extra-articular lesions and systemic complications. Depending on intensity and duration of RA in imaging studies the patients demonstrate narrowing of articular fissures, presence of geodes, erosions, subluxations and/or synostoses. Progressive bone mass loss in the joint involved by the morbid process and in the entire skeleton was also described. Local (periarticular) osteoporosis is linked to the presence of cytokines and growth factors, which regulate reciprocal interactions between osteoclasts, osteoblasts and immune system cells. In the inflamed joint accumulate synoviocytes of fibroblast phenotype, synoviocytes of macrophage phenotype, antigen presenting cells, lymphocytes T, activated lymphocytes B, plasma cells and neutrophils. Increased expression of receptor activator of nuclear factor κB (RANKL), macrophage-colony stimulating factor (M-CSF), presence of TNFα, IL-1, IL-6, IL-7, IL-17 influences pathological loss of bone mass. Rheumatoid arthritis is an important risk factor of generalised osteoporosis and fractures, involved in FRAX (fracture risk assessment) algorythm. Generalised osteoporosis in patients with RA has a multifactorial aetiology. Its development reflects effects of both: factors linked to the disease (presence of proinflammatory cytokines, disability of the patients, applied therapy) and classical risk factors of osteoporosis (e.g. advanced age, sex, post-menopausal period, genetic predisposition, low peak bone mass, low body weight, deficiency of calcium and vitamin D, tobacco smoking).

References

• 1. Adachi J.D., Olszynski W.P., Hanley D.A., Hodsman A.B., KendlerD.L., Siminoski K.G., Brown J., Cowden E.A., Goltzman D., IoannidisG., Josse R.G., Ste-Marie L.G., Tenenhouse A.M., Davison K.S., BlockaK.L., Pollock A.P., Sibley J.: Management of corticosteroid-inducedosteoporosis. Semin. Arthritis Rheum., 2000; 29: 228-251
  Google Scholar
• 2. Adamopoulos I.E., Sabokbar A., Wordsworth B.P., Carr A., FergusonD.J., Athanasou N.A.: Synovial fluid macrophages are capableof osteoclast formation and resorption. J. Pathol., 2006; 208: 35-43
  Google Scholar
• 3. Alves C., Colin E.M., van Oort W.J., Sluimer J.P., Hazes J.M., LuimeJ.J.: Periarticular osteoporosis: a useful feature in the diagnosis ofearly rheumatoid arthritis? Reliability and validity in a cross-sectionaldiagnostic study using dual-energy X-ray absorptiometry.Rheumatology, 2011; 50: 2257-2263
  Google Scholar
• 4. Baek S.H., Lee S.G., Park Y.E., Kim G.T., Kim C.D., Park S.Y.: Increasedsynovial expression of IL-27 by IL-17 in rheumatoid arthritis.Inflamm. Res., 2012; 61: 1339-1345
  Google Scholar
• 5. Broy S.B., Tanner S.B., FRAX® Position Development ConferenceMembers: Official positions for FRAX® clinical regarding rheumatoidarthritis from Joint Official Positions Development Conference of theInternational Society for Clinical Densitometry and International OsteoporosisFoundation on FRAX®. J. Clin. Densitom., 2011; 14: 184-189
  Google Scholar
• 6. Canalis E.: Mechanisms of glucocorticoid action in bone: implicationsto glucocorticoid-induced osteoporosis. J. Clin. Endocrinol.Metab., 1996; 81: 3441-3447
  Google Scholar
• 7. Chen Y., Zheng X., Zou R., Wang J.: Effects of cyclosporin-a onrat skeletal biomechanical properties. BMC Musculoskelet. Disord.,2011; 12: 240
  Google Scholar
• 8. Cohen S.B., Dore R.K., Lane N.E., Ory P.A., Peterfy C.G., Sharp J.T.,van der Heijde D., Zhou L., Tsuji W., Newmark R.; Denosumab RheumatoidArthritis Study Group: Denosumab treatment effects on structuraldamage, bone mineral density, and bone turnover in rheumatoid arthritis:a twelve month, multicenter, randomised, double blind, placebocontrolled, phase II clinical trial. Arthritis Rheum., 2008; 58: 1299-1309
  Google Scholar
• 9. Cooper C., Coupland C., Mitchell M.: Rheumatoid arthritis, corticosteroidtherapy and hip fracture. Ann. Rheum. Dis., 1995; 54: 49-52
  Google Scholar
• 10. Cosman F., Nieves J., Herbert J., Shen V., Lindsay R.: High-doseglucocorticoids in multiple sclerosis patients exert direct effectson the kidney and skeleton. J. Bone Miner. Res., 1994; 9: 1097-1105
  Google Scholar
• 11. Crotti T.N., Smith M.D., Weedon H., Ahern M.J., Findlay D.M.,Kraan M., Tak P.P., Haynes D.R.: Receptor activator NF-κB ligand(RANKL) expression in synovial tissue from patients with rheumatoidarthritis, spondyloarthropathy, osteoarthritis, and from normalpatients: semiquantitative and quantitative analysis. Ann. Rheum.Dis., 2002; 61: 1047-1054
  Google Scholar
• 12. de Rooy D.P., Kälvesten J., Huizinga T.W., van der Helm-van MilA.H.: Loss of metacarpal bone density predicts RA development inrecent-onset arthritis. Rheumatology, 2012; 51: 1037-1041
  Google Scholar
• 13. Deal C.: Bone loss in rheumatoid arthritis: systemic, periarticular,and focal. Curr. Rheumatol. Rep., 2012; 14: 231-237
  Google Scholar
• 14. Deodhar A., Dore R.K., Mandel D., Schechtman J., Shergy W.,Trapp R., Ory P.A., Peterfy C.G., Fuerst T., Wang H., Zhou L., Tsuji W.,Newmark R.: Denosumab-mediated increase in hand bone mineraldensity associated with decreased progression of bone erosion inrheumatoid arthritis patients. Arthritis Care Res., 2010; 62: 569-574
  Google Scholar
• 15. Di Munno O., Delle Sedie A., Rossini M., Adami S.: Disease modifyingantirheumatic drugs and bone mass in rheumatoid arthritis.Clin. Exp. Rheumatol., 2005; 23: 137-144
  Google Scholar
• 16. Diarra D., Stolina M., Polzer K., Zwerina J., Ominsky M.S., DwyerD., Korb A., Smolen J., Hoffmann M., Scheinecker C., van der Heide D.,Landewe R., Lacey D., Richards W.G., Schett G.: Dickkopf-1 is a masterregulator of joint remodeling. Nat. Med., 2007; 13: 156-163
  Google Scholar
• 17. Ding J., Ghali O., Lencel P., Broux O., Chauveau C., DevedjianJ.C., Hardouin P., Magne D.: TNF-α and IL-1β inhibit RUNX2 andcollagen expression but increase alkaline phosphatase activityand mineralization in human mesenchymal stem cells. Life Sci.,2009; 84: 499-504
  Google Scholar
• 18. El Maghraoui A., Rezgi A., Mounach A., Achemlal L., Bezza A.,Ghozlani I.: Prevalence and risk factors of vertebral fractures inwomen with rheumatoid arthritis using vertebral fracture assessment.Rheumatology, 2010; 49: 1303-1310
  Google Scholar
• 19. Fan C., Georgiou K.R., King T.J., Xian C.J.: Methotrexate toxicityin growing long bones of young rats: a model for studying cancerchemotherapy-induced bone growth defects in children. J. Biomed.Biotechnol., 2011; 2011: 903097
  Google Scholar
• 20. Ferraccioli G., Casatta L., Bartoli E.: Increase of bone mineraldensity and anabolic variables in patients with rheumatoid arthritisresistant to methotrexate after cyclosporin A therapy. J. Rheumatol.,1996; 23: 1539-1542
  Google Scholar
• 21. Forsblad D’Elia H., Larsen A., Waltbrand E., Kvist G., MellströmD., Saxne T., Ohlsson C., Nordborg E., Carlsten H.: Radiographic jointdestruction in postmenopausal rheumatoid arthritis is stronglyassociated with generalised osteoporosis. Ann. Rheum. Dis., 2003;62: 617-623
  Google Scholar
• 22. Frattini A., Vezzoni P., Villa A., Sobacchi C.: The dissection ofhuman autosomal recesssive osteopetrosis identifies an osteoclastpoorform due to RANKL deficiency. Cell Cycle, 2007; 6: 3027-3033
  Google Scholar
• 23. Gilbert L., He X., Farmer P., Rubin J., Drissi H., van Wijnen A.J.,Lian J.B., Stein G.S., Nanes M.S.: Expression of the osteoblast differentiationfactor RUNX2 (Cbfa1/AML3/Pebp2αA) is inhibited by tumornecrosis factor-α. J. Biol. Chem., 2002; 277: 2695-2701
  Google Scholar
• 24. Gonzalez A., Maradit Kremers H., Crowson C.S., Nicola P.J., DavisJ.M. 3rd, Therneau T.M., Roger V.L., Gabriel S.E.: The widening mortalitygap between rheumatoid arthritis patients and the generalpopulation. Arthritis Rheum., 2007; 56: 3583-3587
  Google Scholar
• 25. Hall G.M., Spector T.D., Griffin A.J., Jawad A.S., Hall M.L., Doyle D.V.:The effect of rheumatoid arthritis and steroid therapy on bone densityin postmenopausal women. Arthritis Rheum., 1993, 36: 1510-1516
  Google Scholar
• 26. Haugeberg G., Conaghan P.G., Quinn M., Emery P.: Bone lossin patients with active early rheumatoid arthritis: infliximab andmethotrexate compared with methotrexate treatment alone. Explorativeanalysis from a 12-month randomised, double-blind, placebocontrolledstudy. Ann. Rheum. Dis., 2009; 68: 1898-1901
  Google Scholar
• 27. Haugeberg G., Green M.J., Quinn M.A., Marzo-Ortega H., ProudmanS., Karim Z., Wakefield R.J., Conaghan P.G., Stewart S., Emery P.:Hand bone loss in early undifferentiated arthritis: evaluating bonemineral density loss before the development of rheumatoid arthritis.Ann. Rheum. Dis., 2006; 65: 736-740
  Google Scholar
• 28. Haugeberg G., Strand A., Kvien T.K., Kirwan J.R.: Reduced loss ofhand bone density with prednisolone in early rheumatoid arthritis:results from a randomized placebo-controlled trial. Arch. Intern.Med., 2005; 165: 1293-1297
  Google Scholar
• 29. Haugeberg G., Uhlig T., Falch J.A., Halse J.I., Kvien T.K.: Bonemineral density and frequency of osteoporosis in female patientswith rheumatoid arthritis: results from 394 patients in the OsloCounty Rheumatoid Arthritis register. Arthritis Rheum., 2000; 43:522-530
  Google Scholar
• 30. Hein G., Eidner T., Oelzner P., Rose M., Wilke A., Wolf G., FrankeS.: Influence of rituximab on markers of bone remodeling inpatients with rheumatoid arthritis: a prospective open-label pilotstudy. Rheumatol. Int., 2011; 31: 269-272
  Google Scholar
• 31. Hirayama T., Danks L., Sabokbar A., Athanasou N.A.: Osteoclastformation and activity in the pathogenesis of osteoporosis in rheumatoidarthritis. Rheumatology, 2002; 41: 1232-1239
  Google Scholar
• 32. Hofbauer L.C., Gori F., Riggs B.L., Lacey D.L., Dunstan C.R., SpelsbergT.C., Khosla S.: Stimulation of osteoprotegerin ligand and inhibitionof osteoprotegerin production by glucocorticoids in humanosteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-inducedosteoporosis. Endocrinology, 1999; 140: 4382-4389
  Google Scholar
• 33. Hofbauer L.C., Schoppet M.: Clinical implications of the osteoprotegerin/RANKL/RANKsystem for bone and vascular diseases.JAMA, 2004; 292: 490-495
  Google Scholar
• 34. Hoff M., Kvien T.K., Kälvesten J., Elden A., Kavanaugh A., HaugebergG.: Adalimumab reduces hand bone loss in rheumatoid arthritisindependent of clinical response: subanalysis of the PREMIER study.BMC Musculoskelet. Disord., 2011; 12: 54
  Google Scholar
• 35. Hooyman J.R., Melton L.J. 3rd, Nelson A.M., O’Fallon W.M., RiggsB.L.: Fractures after rheumatoid arthritis. A population-based study.Arthritis Rheum., 1984; 27: 1353-1361
  Google Scholar
• 36. Jamison M., Neuberger G.B., Miller P.A.: Correlates of falls andfear of falling among adults with rheumatoid arthritis. ArthritisRheum., 2003; 49: 673-680
  Google Scholar
• 37. Jimenez-Boj E., Redlich K., Türk B., Hanslik-Schnabel B., WanivenhausA., Chott A., Smolen J.S., Schett G.: Interaction betweensynovial inflammatory tissue and bone marrow in rheumatoid arthritis.J. Immunol., 2005; 175: 2579-2588
  Google Scholar
• 38. Kaneki H., Guo R., Chen D., Yao Z., Schwarz E.M., Zhang Y.E.,Boyce B.F., Xing L.: Tumor necrosis factor promotes Runx2 degradationthrough up-regulation of Smurf1 and Smurf2 in osteoblasts.J. Biol. Chem., 2006; 281: 4326-4333
  Google Scholar
• 39. Keller K.K., Thomsen J.S., Stengaard-Pedersen K., Dagnæs-HansenF., Nyengaard J.R., Hauge E.M.: Bone formation and resorptionare both increased in experimental autoimmune arthritis. PloS One,2012; 7: e53034
  Google Scholar
• 40. Kmieć Z., Sokołowska I.: Rola cytokin z rodziny czynnika martwicynowotworów w przebiegu reumatoidalnego zapalenia stawów– nowe możliwości terapii. Pol. Merkur. Lekarski, 2007; 22: 300-304
  Google Scholar
• 41. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., KotakeS., Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H.,Morinaga T., Higashio K., Martin T.J., Suda T.: Tumor necrosis factorα stimulates osteoclast differentiation by a mechanism independentof the ODF/RANKL-RANK interaction. J. Exp. Med., 2000; 191: 275-286
  Google Scholar
• 42. Kokebie R., Aggarwal R., Lidder S., Hakimiyan A.A., Rueger D.C.,Block J.A., Chubinskaya S.: The role of synovial fluid markers ofcatabolism and anabolism in osteoarthritis, rheumatoid arthritisand asymptomatic organ donors. Arthritis Res. Ther., 2011; 13: R50
  Google Scholar
• 43. Kontny E.: Pathogenesis of rheumatoid arthritis. Part II – innateimmunity, new therapeutic targets. Reumatology, 2011; 49: 115-121
  Google Scholar
• 44. Korczowska I., Łącki J.K., Hrycaj P.: Influence of infliximab oncytokines network and markers of bone remodeling in rheumatoidarthritis patients. Yonsei Med. J., 2013; 54: 183-188
  Google Scholar
• 45. Korczowska I., Olewicz-Gawlik A., Trefler J., Hrycaj P., Łącki J.K.:Does low-dose and short-term glucocorticoids treatment increasethe risk of osteoporosis in rheumatoid arthritis female patients?Clin. Rheumatol., 2008; 27: 565-572
  Google Scholar
• 46. Kryśkiewicz E., Lorenc R.S.: Regulacja metabolizmu kostnego.Terapie innowacyjne w osteoporozie. Pol. Arch. Med. Wew., 2010; 120 (Suppl. 1): 31-39
  Google Scholar
• 47. Lam J., Takeshita S., Barker J.E., Kanagawa O., Ross F.P., TeitelbaumS.L.: TNF-α induces osteoclastogenesis by direct stimulationof macrophages exposed to permissive levels of RANK ligand. J. Clin.Invest., 2000; 106: 1481-1488
  Google Scholar
• 48. Larsen A., Dale K., Eek M.: Radiographic evaluation of rheumatoidarthritis and related conditions by standard reference films.Acta Radiol. Diagn., 1977; 18: 481-491
  Google Scholar
• 49. Li X., Yuan F.L., Lu W.G., Zhao Y.Q., Li C.W., Li J.P., Xu R.S.: Therole of interleukin-17 in mediating joint destruction in rheumatoidarthritis. Biochem. Biophys. Res. Commun., 2010; 397: 131-135
  Google Scholar
• 50. Lodder M.C., de Jong Z., Kostense P.J., Molenaar E.T., Staal K.,Voskuyl A.E., Hazes J.M., Dijkmans B.A., Lems W.F.: Bone mineraldensity in patients with rheumatoid arthritis: relation between diseaseseverity and low bone mineral density. Ann. Rheum. Dis., 2004;63: 1576-1580
  Google Scholar
• 51. Lodder M.C., Haugeberg G., Lems W.F., Uhlig T., Orstavik R.E.,Kostense P.J., Dijkmans B.A., Kvien T.K., Woolf A.D., Oslo-Truro-Amsterdam(OSTRA) Collaborative Study: Radiographic damage associatedwith low bone mineral density and vertebral deformities inrheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) CollaborativeStudy. Arthritis Rheum., 2003; 49: 209-215
  Google Scholar
• 52. Macovei L., Ancuta C., Belibou C., Chirieac R.: Bone mineral densityin patients with rheumatoid arthritis. Rev. Med. Chir. Soc. Med.Nat., 2011; 115: 723-730
  Google Scholar
• 53. Marie P.J.: Transcription factors controlling osteoblastogenesis.Arch. Biochem. Biophys., 2008; 473: 98-105
  Google Scholar
• 54. Mazzantini M., Di Munno O., Incerti-Vecchi L., Pasero G.: Vertebralbone mineral density changes in female rheumatoid arthritispatients treated with low-dose methotrexate. Clin. Exp. Rheumatol.,2000; 18: 327-331
  Google Scholar
• 55. Mazzantini M., Di Munno O., Sinigaglia L., Bianchi G., RossiniM., Mela Q., Del Puente A., Frediani B., Cantatore F., Adami S.: Effectof cyclosporine A on bone density in female rheumatoid arthritispatients: results from a multicenter, cross-sectional study. Clin. Exp.Rheumatol., 2007; 25: 709-715
  Google Scholar
• 56. Minaur N.J., Kounali D., Vedi S., Compston J.E., Beresford J.N., BhallaA.K.: Methotrexate in the treatment of rheumatoid arthritis. II. Invivo effects on bone mineral density. Rheumatology, 2002; 41: 741-749
  Google Scholar
• 57. Miranda-Carús M.E., Benito-Miguel M., Balsa A., Cobo-IbánezT., Pérez de Ayala C., Pascual-Salcedo D., Martin-Mola E.: Peripheralblood T lymphocytes from patients with early rheumatoid arthritisexpress RANKL and interleukin-15 on the cell surface and promoteosteoclastogenesis in autologous monocytes. Arthritis Rheum., 2006;54: 1151-1164
  Google Scholar
• 58. Natsui K., Tanaka K., Suda M., Yasoda A., Sakuma Y., Ozasa A.,Ozaki S., Nakao K.: High-dose glucocorticoid treatment induces rapidloss of trabecular bone mineral density and lean body mass. Osteoporos.Int., 2006; 17: 105-108
  Google Scholar
• 59. Nemeth K., Schoppet M., Al-Fakhri N., Helas S., Jessberger R.,Hofbauer L.C., Goettsch C.: The role of osteoclast-associated receptorin osteoimmunology. J. Immunol., 2011; 186: 13-18
  Google Scholar
• 60. O’Brien C.A., Jia D., Plotkin L.I., Bellido T., Powers C.C., StewartS.A., Manolagas S.C., Weinstein R.S.: Glucocorticoids act directly onosteoblasts and osteocytes to induce their apoptosis and reducebone formation and strength. Endocrinology, 2004; 145: 1835-1841
  Google Scholar
• 61. Okamoto K., Takayanagi H.: Regulation of bone by the adaptiveimmune system in arthritis. Arthritis Res. Ther., 2011; 13: 219
  Google Scholar
• 62. Orita Y., Yamamoto H., Kohno N., Sugihara M., Honda H., KawamataS., Mito S., Soe N.N., Yoshizumi M.: Role of osteoprotegerin inarterial calcification: development of new animal model. Arterioscler.Thromb. Vasc. Biol., 2007; 27: 2058-2064
  Google Scholar
• 63. Pawlak-Buś K., Leszczyński P.: Inhibitory Wnt/β-kateniny w terapiiobniżonej masy kostnej – nowe perspektywy w leczeniu osteoporozy?Endokrynol. Otyłość, 2011; 7: 11-15
  Google Scholar
• 64. Przedlacki J.: Zasady postępowania diagnostyczno-leczniczegow osteoporozie u osób dodorsłych Zakład Wydawniczo-PoligraficznyJerzy Krawczyk, Warszawa 2010
  Google Scholar
• 65. Rell-Bakalarska M.: Przyczyny osteoporozy wtórnej. Chorobyukładu ruchu. W: Osteoporoza wtórna osób dorosłych, red.: PrzedlackiJ., Rell-Bakalarska M., Warszawa, 2007: 47-60
  Google Scholar
• 66. Roux C.: Osteoporosis in inflammatory joint diseases. Osteoporos.Int., 2011; 22: 421-433
  Google Scholar
• 67. Scott D.L., Wolfe F., Huizinga T.W.: Rheumatoid arthritis. Lancet,2010; 376: 1094-1108
  Google Scholar
• 68. Seriolo B., Ferretti V., Sulli A., Caratto E., Fasciolo D., Cutolo M.:Serum osteocalcin levels in premenopausal rheumatoid arthritispatients. Ann. N.Y. Acad. Sci., 2002; 966: 502-507
  Google Scholar
• 69. Smith J.B., Haynes M.K.: Rheumatoid arthritis – a molecular understanding.Ann. Intern. Med., 2002; 136: 908-922
  Google Scholar
• 70. Sobacchi C., Frattini A., Guerrini M.M., Abinun M., PangrazioA., Susani L., Bredius R., Mancini G., Cant A., Bishop N., GrabowskiP, Del Fattore A., Messina C., Errigo G., Coxon F.P. i wsp.: Osteoclastpoorhuman osteopetrosis due to mutations in the gene encodingRANKL. Nat. Genet., 2007; 39: 960-962
  Google Scholar
• 71. Stava C.J., Jimenez C., Hu M.I., Vassilopoulou-Sellin R.: Skeletal sequelaeof cancer and cancer treatment. J. Cancer Surviv., 2009; 3: 75-88
  Google Scholar
• 72. Svensson B., Boonen A., Atbertsson K., van der Heijde D., KellerC., Hafstrӧm I.: Low-dose prednisolone in addition to the initialdisease-modifying antirheumatic drug in patients with early activerheumatoid arthritis reduces joint destruction and increasesthe remission rate: a two-year randomized trial. Arthritis Rheum.,2005; 52: 3360-3370
  Google Scholar
• 73. Tascioglu F., Oner C., Armagan O.: The effect of low-dose methotrexateon bone mineral density in patients with early rheumatoidarthritis. Rheumatol. Int., 2003; 23: 231-235
  Google Scholar
• 74. Teitelbaum S.L.: Osteoclasts: what do they do and how do theydo it? Am. J. Pathol., 2007; 170: 427-435
  Google Scholar
• 75. Terpos E., Fragiadaki K., Konsta M., Bratengeier C., PapatheodorouA., Sfikakis P.P.: Early effects of IL-6 receptor inhibition on bonehomeostasis: a pilot study in women with rheumatoid arthritis. Clin.Exp. Rheumatol., 2011; 29: 921-925
  Google Scholar
• 76. Tourinho T.F., Stein A., Castro J.A., Brenol J.C.: Rheumatoid arthritis:evidence for bone loss in premenopausal women. J. Rheumatol.,2005; 32: 1020-1025
  Google Scholar
• 77. van Staa T.P., Geusens P., Bijlsma J.W., Leufkens H.G., CooperC.: Clinical assessment of the long-term risk of fracture in patientswith rheumatoid arthritis. Arthritis Rheum., 2006; 54: 3104-3112
  Google Scholar
• 78. Veldhuis J.D.: Patophysiology of suppressed reproductive axesin men and women receiving exogenous glucocorticoids and/or exhibitingendogenous hypercortisolism. Osteoporos. Int., 1999; 9: S3
  Google Scholar
• 79. Vis M., Havaardsholm E.A., Haugeberg G., Uhlig T., Voskuyl A.E.,van de Stadt R.J., Dijkmans B.A., Woolf A.D., Kvien T.K., Lems W.F.:Evaluation of bone mineral density, bone metabolism, osteoprotegerinand receptor activator of the NFκB ligand serum levels duringtreatment with infliximab in patients with rheumatoid arthritis.Ann. Rheum. Dis., 2006; 65: 1495-1499
  Google Scholar
• 80. Voorzanger-Rousselot N., Ben-Tabassi N.C., Garnero P.: Oppositerelationship between circulating Dkk-1 and cartilage breakdown inpatients with rheumatoid arthritis and knee osteoarthritis. Ann.Rheum. Dis., 2009; 68: 1513-1514
  Google Scholar
• 81. Wada C., Kataoka M., Seto H., Hayashi N., Kido J., Shinohara Y.,Nagata T.: High-turnover osteoporosis is induced by cyclosporin A inrats. J. Bone Miner. Metab., 2006; 24: 199-205
  Google Scholar
• 82. Wei S., Kitaura H., Zhou P., Ross F.P., Teitelbaum S.L.: IL-1 mediatesINF-induced osteoclastogenesis. J. Clin. Invest., 2005; 115:282-290
  Google Scholar
• 83. Weinstein R.S., Jilka R.L., Parfitt A.M., Manolagas S.C.: Inhibitionof osteoblastogenesis and promotion of apoptosis of osteoblasts andosteocytes by glucocorticoids. Potential mechanisms of their deleteriouseffects on bone. J. Clin. Invest., 1998; 102: 274-282
  Google Scholar
• 84. Welsing P.M., Landewé R.B., van Riel P.L., Boers M., van GestelA.M., van der Linden S., Swinkels H.L., van der Heijde D.M.: The relationshipbetween disease activity and radiologic progression inpatients with rheumatoid arthritis: a longitudinal analysis. ArthritisRheum., 2004; 50: 2082-2093
  Google Scholar
• 85. Wijbrandts C.A., Klaasen R., Dijkgraaf M.G., Gerlag D.M., vanEck-Smit B.L., Tak P.P.: Bone mineral density in rheumatoid arthritispatients 1 year after adalimumab therapy: arrest of bone loss. Ann.Rheum. Dis., 2009; 68: 373-376
  Google Scholar
• 86. Wolfe F., Mitchell D.M., Sibley J.T., Fries J.F., Bloch D.A., WilliamsC.A., Spitz P.W., Haga M., Kleinheksel S.M., Cathey M.A.: The mortalityof rheumatoid arthritis. Arthritis Rheum., 1994; 37: 481-494
  Google Scholar
• 87. Wróbel T., Mazur G., Lindner K., Ziółkowska J.: IL-17 as a mediatorof inflammation and angiogenesis. Adv. Clin. Exp. Med., 2005;14: 555-558
  Google Scholar
• 88. Zdzisińska B., Kandefer-Szerszeń M.: Rola RANK/RANKL i OPGw szpiczaku plazmocytowym. Postępy Hig. Med. Dośw., 2006; 60:471-482
  Google Scholar

Full text